Get the Stockscreener App
38.35
0.22%
-0.06
Procept Biorobotics Corp stock is traded at $38.35, with a volume of 1.34M.
It is down -0.22% in the last 24 hours and down -32.35% over the past month.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
See More
Previous Close:
$38.41
Open:
$38.41
24h Volume:
1.34M
Relative Volume:
1.30
Market Cap:
$2.12B
Revenue:
$249.12M
Net Income/Loss:
$-90.19M
P/E Ratio:
-22.56
EPS:
-1.7
Net Cash Flow:
$-88.21M
1W Performance:
-22.73%
1M Performance:
-32.35%
6M Performance:
-41.93%
1Y Performance:
-37.31%
1-Day Range:
$37.32
$39.55
1-Week Range:
$37.12
$49.90
52-Week Range:
$37.12
$103.81
Procept Biorobotics Corp Stock (PRCT) Company Profile
Name
Procept Biorobotics Corp
Sector
Industry
Phone
(650) 232-9832
Address
150 BAYTECH DRIVE, SAN JOSE
Compare PRCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRCT
Procept Biorobotics Corp
|
38.35 | 2.54B | 249.12M | -90.19M | -88.21M | -1.70 |
|
ABT
Abbott Laboratories
|
131.25 | 227.88B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.84 | 152.55B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
377.20 | 143.34B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.78 | 114.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.16 | 46.15B | 5.69B | 4.14B | 577.90M | 6.96 |
Procept Biorobotics Corp Stock (PRCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Stephens | Overweight |
| Jul-07-25 | Initiated | Oppenheimer | Perform |
| Dec-02-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Initiated | Jefferies | Hold |
| Aug-11-23 | Initiated | Piper Sandler | Overweight |
| May-31-23 | Initiated | William Blair | Outperform |
| Oct-31-22 | Initiated | BTIG Research | Neutral |
| Oct-25-22 | Initiated | Truist | Buy |
| Sep-02-22 | Initiated | Wells Fargo | Overweight |
| Jul-15-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Goldman | Neutral |
| Oct-11-21 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | SVB Leerink | Outperform |
View All
Procept Biorobotics Corp Stock (PRCT) Latest News
Procept BioRobotics Grows Fast Despite Wall Street Skepticism - Finimize
PROCEPT BioRobotics Reports Strong Q2 2025 Growth - TipRanks
Procept Biorobotics Reports Strong Q2 Growth Amid Challenges - TipRanks
PROCEPT BioRobotics outlines $325.5M 2025 revenue target amid leadership transition and margin expansion - MSN
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2025 Earnings Call Transcript - MSN
What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S After Its 34% Share Price Crash - simplywall.st
Why PROCEPT BioRobotics Corporation stock attracts strong analyst attentionFast Return Equity Trade Forecast Points to Small Caps - beatles.ru
Edwards’ Longtime TAVR Leader is Named PROCEPT BioRobotics CEO - Medical Product Outsourcing
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $55 to $83 - 富途牛牛
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$65.75 Price Target - simplywall.st
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Qiagen (QGEN) - The Globe and Mail
PROCEPT BioRobotics 2025 Q2 Earnings Improved Losses Amid Revenue Surge - AInvest
PROCEPT BioRobotics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Buy Rating for PROCEPT BioRobotics: Growth Potential and Stability Amid Sales Beat and Improved Guidance - TipRanks
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $85 to $85 - 富途牛牛
Procept Biorobotics Corp.’s Aquablation Therapy: A Promising Update for Prostate Cancer Treatment - TipRanks
Earnings call transcript: Procept BioRobotics Q2 2025 beats forecasts, stock dips - Investing.com
Truist Lowers Price Target on PROCEPT BioRobotics to $64 From $70, Keeps Buy Rating - MarketScreener
Why PROCEPT BioRobotics Shares Are Tumbling - TipRanks
Wells Fargo lowers Procept BioRobotics stock price target on delayed system replacements - Investing.com Canada
Optimistic Outlook on PROCEPT BioRobotics Amidst Medtech Sector Challenges - TipRanks
PROCEPT BioRobotics (PRCT): Assessing the Path to Profitability Amid Leadership Transition and Global Expansion - AInvest
Procept (PRCT) Q2 Revenue Jumps 48% - The Globe and Mail
Procept (PRCT) Q2 Revenue Jumps 48% - The Motley Fool
PROCEPT BioRobotics (PRCT) Earnings Transcript - Mitrade
Procept Biorobotics earnings beat by $0.06, revenue topped estimates - Investing.com South Africa
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Zimmer Biomet (ZBH) Q2 Revenue Jumps 7% - AOL.com
PROCEPT BioRobotics Q2 revenue up 48% YoY to $79.2mln. - AInvest
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results - TradingView
Procept BioRobotics Q2 revenue up 48%, beats estimates - MarketScreener
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - GlobeNewswire
Procept Biorobotics stock hits 52-week low at 47.0 USD - Investing.com
Procept Biorobotics stock hits 52-week low at 47.0 USD By Investing.com - Investing.com Canada
Edwards Veteran Wood Departs for CEO Gig - Orange County Business Journal
Should I hold or sell PROCEPT BioRobotics Corporation stock in 2025Unlock expert stock analysis and alerts - Jammu Links News
Is it the right time to buy PROCEPT BioRobotics Corporation stockBuild a diversified portfolio for sustainable growth - Jammu Links News
What drives PROCEPT BioRobotics Corporation stock priceGet professional advice for portfolio optimization - Jammu Links News
When is PROCEPT BioRobotics Corporation stock expected to show significant growthDynamic investment opportunities - Jammu Links News
How does PROCEPT BioRobotics Corporation compare to its industry peersRapid wealth multiplication - Jammu Links News
What are the latest earnings results for PROCEPT BioRobotics CorporationRemarkable growth - Jammu Links News
What is PROCEPT BioRobotics Corporation company’s growth strategyGet expert analysis on top stock picks - Jammu Links News
Is PROCEPT BioRobotics Corporation a growth stock or a value stockInvest smarter with daily stock recommendations - Jammu Links News
Published on: 2025-08-03 05:58:47 - Jammu Links News
What institutional investors are buying PROCEPT BioRobotics Corporation stockAccelerated wealth expansion - Jammu Links News
PROCEPT BioRobotics to Announce Q2 2025 Earnings on August 6, 2025 - AInvest
Quant Funds Rotate Into PROCEPT BioRobotics Corporation StockTechnical Entry Strategy for Beginners Explained - metal.it
Market reaction to PROCEPT BioRobotics Corporation’s recent newsSmart Allocation Stock Pick Insights Gaining Interest - metal.it
RSI Alert: PROCEPT BioRobotics (PRCT) Now Oversold - Nasdaq
What are analysts’ price targets for PROCEPT BioRobotics Corporation in the next 12 monthsBeginner Investor Planner With Proven Results - Jammu Links News
Will PROCEPT BioRobotics Corporation (PRCT) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Procept Biorobotics Corp Stock (PRCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Procept Biorobotics Corp Stock (PRCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Desai Antal Rohit | Director |
Jun 11 '25 |
Sale |
63.38 |
25,000 |
1,584,525 |
39,363 |
| Desai Antal Rohit | Director |
Jun 12 '25 |
Sale |
61.49 |
25,000 |
1,537,256 |
14,363 |
0.19%
1.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):